Literature DB >> 17768676

Role of lipoamide dehydrogenase and metallothionein on 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced neurotoxicity.

Muralikrishnan Dhanasekaran1, Christian B Albano, Lori Pellet, Senthilkumar S Karuppagounder, Subramaniam Uthayathas, Vishnu Suppiramaniam, Holly Brown-Borg, Manuchair Ebadi.   

Abstract

In the present study, we investigated the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on lipoamide dehydrogenase activity and metallothionein content. Lipoamide dehydrogenase is a flavoprotein enzyme, which reduces lipoamide and low molecular weight thiols. This enzyme has also been involved in the conversion of ubiquinone (coenzyme Q-10, oxidized form) to ubiquinol (reduced form). Lipoamide dehydrogenase activity was measured spectrophotometrically following its incubation with different doses of MPTP, MPP+, and divalent metals. MPTP at higher concentrations inhibited the lipoamide dehydrogenase activity, whereas it's potent toxic metabolite 1-methyl-4-phenylpyridinium (MPP+) had a similar effect at lower concentration. Calcium and copper did not affect the enzyme activity at any of the doses tested, whereas, zinc dose dependently enhanced the lipoamide dehydrogenase activity. Additionally, levels of metallothionein in the mouse nigrostriatal system were measured by cadmium affinity method following administration of MPTP. Metallothionein content was significantly reduced in the substantia nigra (SN), and not in the nucleus caudatus putamen (NCP) following a single administration of MPTP (30 mg/kg, i.p.). Our results suggests that both lipoamide dehydrogenase activity and metallothionein levels may be critical for dopaminergic neuronal survival in Parkinson's disease and provides further insights into the neurotoxic mechanisms involved in MPTP-induced neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17768676     DOI: 10.1007/s11064-007-9468-9

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  36 in total

Review 1.  The emerging role of coenzyme Q-10 in aging, neurodegeneration, cardiovascular disease, cancer and diabetes mellitus.

Authors:  Muralikrishnan Dhanasekaran; Jun Ren
Journal:  Curr Neurovasc Res       Date:  2005-12       Impact factor: 1.990

2.  Metallothionein isoforms provide neuroprotection against 6-hydroxydopamine-generated hydroxyl radicals and superoxide anions.

Authors:  M Ebadi; M Hiramatsu; W J Burke; D G Folks; M A el-Sayed
Journal:  Proc West Pharmacol Soc       Date:  1998

3.  The specific vulnerability of the substantia nigra to MPTP is related to the presence of transition metals.

Authors:  J Poirier; J Donaldson; A Barbeau
Journal:  Biochem Biophys Res Commun       Date:  1985-04-16       Impact factor: 3.575

4.  Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced neurotoxicity.

Authors:  K P Mohanakumar; D Muralikrishnan; B Thomas
Journal:  Brain Res       Date:  2000-05-12       Impact factor: 3.252

5.  Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys.

Authors:  H Mochizuki; H Imai; K Endo; K Yokomizo; Y Murata; N Hattori; Y Mizuno
Journal:  Neurosci Lett       Date:  1994-02-28       Impact factor: 3.046

6.  In vivo hydroxyl radical generation in the striatum following systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.

Authors:  B Thomas; D Muralikrishnan; K P Mohanakumar
Journal:  Brain Res       Date:  2000-01-03       Impact factor: 3.252

Review 7.  The physiological role of zinc as an antioxidant.

Authors:  T M Bray; W J Bettger
Journal:  Free Radic Biol Med       Date:  1990       Impact factor: 7.376

8.  SKF-38393, a dopamine receptor agonist, attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.

Authors:  D Muralikrishnan; M Ebadi
Journal:  Brain Res       Date:  2001-02-23       Impact factor: 3.252

9.  Ubiquinone protects cultured neurons against spontaneous and excitotoxin-induced degeneration.

Authors:  A Favit; F Nicoletti; U Scapagnini; P L Canonico
Journal:  J Cereb Blood Flow Metab       Date:  1992-07       Impact factor: 6.200

10.  Differential recovery of dopamine synthetic enzymes following MPTP and the consequences of GM1 ganglioside treatment.

Authors:  M Hadjiconstantinou; N H Neff
Journal:  Eur J Pharmacol       Date:  1990-05-31       Impact factor: 4.432

View more
  3 in total

1.  Up-regulation of metallothionein gene expression in parkinsonian astrocytes.

Authors:  Gregory J Michael; Sharmin Esmailzadeh; Linda B Moran; Lynne Christian; Ronald K B Pearce; Manuel B Graeber
Journal:  Neurogenetics       Date:  2011-07-29       Impact factor: 2.660

2.  Effects of hydroxysafflor yellow A in the attenuation of MPTP neurotoxicity in mice.

Authors:  B Han; H Zhao
Journal:  Neurochem Res       Date:  2009-08-13       Impact factor: 3.996

Review 3.  Copper and copper proteins in Parkinson's disease.

Authors:  Sergio Montes; Susana Rivera-Mancia; Araceli Diaz-Ruiz; Luis Tristan-Lopez; Camilo Rios
Journal:  Oxid Med Cell Longev       Date:  2014-01-08       Impact factor: 6.543

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.